One GLP-1 drug has already been all the way through this in the United States. Liraglutide — Victoza for type 2 diabetes, Saxenda for weight management — now has eleven approved generics, and the federal file that records what pharmacies pay to buy drugs has been tracking the result for two years. That series is the closest thing available to an answer about what happens after a GLP-1 patent lapses, and it does not say what the word generic usually implies. The parallel question for semaglutide, where protection has lapsed abroad but not here, is handled in the semaglutide patent article.
The approvals, and which brand each one copies
The Orange Book product file records eleven abbreviated applications for liraglutide injection, every one of them at the same strength — 18 mg in 3 mL, or 6 mg/mL. The first was approved on December 23, 2024 and the most recent on July 1, 2026.[1]
They are not all copies of the same product. Victoza and Saxenda hold the same ingredient at the same strength in the same dosage form, so the register has to distinguish them, and it does so with a digit on the end of the therapeutic-equivalence code. FDA’s August 2026 guidance explains the rule: a three-character code is assigned where more than one reference listed drug of the same strength sits under one product heading, and abbreviated applications referencing the first get the number 1, those referencing the second get the number 2.[2]
Victoza carries AP1 and Saxenda carries AP2. Of the eleven generics, eight carry AP1 — they copy the diabetes product — and three carry AP2, copying the weight-management one.[1] That split is the first thing a reader should take from the register, because it means generic liraglutide is not one event with one price.
A timing detail the exclusivity file makes visible
The exclusivity file carries exactly one entry against any liraglutide abbreviated application: Teva’s, application 214568, coded PC and dated February 24, 2026.[1] Teva’s was the first AP2 approval, on August 27, 2025. The second and third AP2 approvals — Biocon’s 217063 and Orbicular’s 217234 — are both dated February 24, 2026, the day that entry expired.[1] Six months of one company, then two more on the same morning.
The patent file complicates the usual story in the other direction. The formulation patent listed against both Victoza and Saxenda, US 8,114,833, expired August 13, 2025, with a pediatric extension to February 13, 2026. A second listed patent, US 9,968,659, carries a use-code designation and runs to January 9, 2037, with a pediatric extension to July 9, 2037.[1] Generics were being approved from December 2024 onward regardless. “A listed patent runs to 2037” and “generics are on the market” are compatible statements, and anyone reading the last date on a patent list as the date competition starts is reading it wrong.
What it did to the price, month by month
The National Average Drug Acquisition Cost file is a federal survey of what retail pharmacies actually pay to buy a drug. It is not a retail price, not a cash-pay price and not a telehealth price, but it is the one number in this whole subject that is published, dated and national.
The first liraglutide product the file classified as generic appeared on September 18, 2024, at $72.99 per mL for the three-pen carton, against $87.47 for Victoza’s the same week.[3] That is a discount of 16.6%. It is also not, strictly, a generic: that product’s national drug code resolves in the openFDA directory to Teva under application NDA 022341 — Victoza’s own application — with a marketing category of NDA authorized generic.[4] The brand company had licensed its own product under a plain label three months before any abbreviated application was approved.
Then the real entrants arrived, and the line kept falling: the same three-pen carton was $49.76 per mL on December 17, 2025 and $32.00 on August 19, 2026 — 63.6% below the brand.[3] Seven different labelers now list liraglutide in that file.[3]
The brand did nothing. Victoza’s three-pen rate was $87.47 in September 2024 and $87.81 in August 2026 — a rise of 0.4% — and Saxenda’s went from $86.63 to $87.14 over the same window.[3] Nothing in two years of generic competition moved the branded line at all. Why a list price and a paid price behave so differently is set out in the price variation article.
Two regimens, two discounts
Here is where the single headline number breaks. Victoza’s maintenance dose is 1.8 mg daily, which at 6 mg/mL is 0.3 mL a day, or 9 mL over 30 days — exactly one three-pen carton. Saxenda’s maintenance dose is 3.0 mg daily, which is 0.5 mL a day, or 15 mL over 30 days — one five-pen carton.
The file prices those cartons differently. The three-pen generic is $32.00 per mL and the five-pen generic is $47.69 per mL — 49% more for the larger pack.[3] Run the month:
A month of the diabetes regimen costs a pharmacy $790.33 in brand and $288.02 in generic, a reduction of 63.6%. A month of the weight-management regimen costs $1,307.06 in brand and $715.42 in generic, a reduction of 45.3%.[3] Same molecule, same strength, same file, same week. The five-pen carton whose national drug code resolves to Teva’s abbreviated application 214568 — the Saxenda-referenced one — is the more expensive per milliliter of the two.[4]
A page that reports “generic liraglutide is 64% cheaper” quotes a real figure from a federal file and hands a weight-loss reader a number that is eighteen points off for their regimen, before the pharmacy’s markup is added at all. What a prescription turns into over twelve months is the subject of the annual cost article, and the cost calculator builds that figure from a quoted rate rather than from a register.
The counterexample: one entrant is not competition
Exenatide went generic too, and it went differently. One abbreviated application, Amneal’s 206697, was approved on November 19, 2024, and every brand exenatide product — Byetta, Bydureon and Bydureon BCise — is recorded as discontinued, which leaves the generic itself carrying the reference standard designation.[1]
With a single supplier, the acquisition cost went the wrong way. The generic pen first appeared in the file on October 22, 2025 at $277.52 per mL and stood at $300.17 on July 22, 2026 — a rise of 8.2% — against a last recorded brand rate of $340.10 from February 2025.[3] Eleven months after approval the sole generic sat 11.7% below a product nobody was selling, and was climbing. Liraglutide’s 63.6% came from seven labelers, not from the word generic.
What the dates say about the drugs people are actually buying
No abbreviated application exists for semaglutide or tirzepatide. Every semaglutide and tirzepatide product in the Orange Book is a new drug application held by its originator.[1]
For tirzepatide the register gives two kinds of date. New-chemical-entity exclusivity is recorded against every product in both Lilly applications, 215866 and 217806, expiring May 13, 2027, which is five years from the first approval — the period during which federal regulation bars submission of an abbreviated application for the same active moiety — except that one carrying a certification of patent invalidity or noninfringement may be submitted after four.[1][5] Zepbound carries three further entries running to November 2026, October 2027 and December 2027, and the Mounjaro application one to December 2028.[1]
The patents run much longer. The earliest-expiring listed tirzepatide patent, US 9,474,780, is flagged against both the drug substance and the drug product and expires May 13, 2036. Eight more listed patents expire on June 14 or July 22 of 2039, and one, US 12,295,987, runs to December 30, 2041.[1]
None of those is a launch date. Liraglutide’s own file shows why: generics were approved with a listed patent still running to 2037, and the first product priced as a generic arrived under the brand’s own application. A date on a register bounds what is possible; it does not schedule anything.
What is not known, and what a compounded vial is not
Several things should be named rather than filled in. It is not known when an abbreviated application for semaglutide or tirzepatide will be submitted, approved or marketed, because none has been. It is not known what a cash telehealth price does when an acquisition cost falls, because that price is set by a seller rather than by a file. And it is not known how the later listed tirzepatide patents will be resolved, because that is litigation rather than a date.
One thing is settled. A compounded preparation is not a generic and does not become one when a patent lapses. Generics are approved products shown to be equivalent to a named reference; compounded drugs are not FDA-approved and the FDA does not review them for safety, efficacy or quality before they are dispensed. The difference is worked through in the compounded-versus-brand article, and why a peptide copy sits awkwardly between two regulatory routes in the biosimilars article.